Gastroparesis is a condition characterised by delayed gastric emptying, where the stomach takes longer than normal to empty its contents into the small intestine
FDA has approved LEROCHOL (lerodalcibep-liga), a novel third-generation PCSK9 inhibitor from LIB Therapeutics, for adults with elevated LDL cholesteroladding a differentiated option to the lipid-lowering biologics market
Greek yogurt and cottage cheese : Soft protein sources that are easier to eat when solid food feels unappealing
This provides twelve or more unique injection zones and virtually eliminates the risk of overusing any single spot
It targets three key hormone receptors at the same time: GLP-1 (glucagon-like peptide-1) Stimulates insulin release Reduces glucagon secretion Helps regulate blood sugar GIP (glucose-dependent insulinotropic polypeptide) Enhances insulin response Improves insulin sensitivity Glucagon Receptors Increases energy expenditure Promotes satiety and appetite control This triagonist design offers a multifaceted attack on metabolic dysfunction, addressing blood sugar, appetite, and energy usage all at once
Cardiovascular Benefits: 20% lower risk of major adverse cardiovascular events in patients with type 2 diabetes and heart disease
